A Randomized Controlled Trial Comparing the Efficacy and Safety of IDegLira Versus Basal-Bolus in Patients With Poorly Controlled Type 2 Diabetes and Very High HbA1c ≥9-15%: DUAL HIGH Trial.

Galindo RJ, Moazzami B, Scioscia MF, Zambrano C, Albury BS, Saling J, Vellanki P, Pasquel FJ, Davis GM, Fayfman M, Peng L, Umpierrez GE

Diabetes care1 Sept 2023Cited by 13 (Europe PMC)

PMID37459574PMCIDPMC10465828DOI10.2337/dc22-2426PepBankPUB-37459574

Source link PubMedAsk about this study

Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and HbA1c 9.0-15.0%, the fixed combination IDegLira (insulin degludec plus liraglutide) did not differ significantly from basal-bolus insulin in HbA1c reduction.
In plain wordsIn adults with very high HbA1c, a combined insulin and liraglutide product lowered HbA1c about as much as basal-bolus insulin.
Peptide
Liraglutide
Outcome
No significant changeHbA1c reduction
Study
n = 145
Comparator
Basal-bolus insulin
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c reduction
3.18%
IDegLira
HbA1c reduction
3%
basal-bolus
estimated treatment difference
0.18%
IDegLira vs basal-bolus
Source sentences
Summary
Among 145 participants (HbA1c 10.8% ± 1.3), there was no statistically significant difference in HbA1c reduction (3.18% ± 2.29 vs. 3.00% ± 1.79, P = 0.65; estimated treatment difference (ETD) 0.18%, 95% CI -0.59, 0.94) between the IDegLira and basal-bolus groups.
1 context sentence(design, population, supporting numbers)
Summary · context
This randomized trial compared the efficacy and safety of insulin degludec and liraglutide (IDegLira) and basal-bolus among participants with high HbA1c ≥9.0-15.0%, previously treated with 2 or 3 oral agents and/or basal insulin, allocated (1:1) to basal-bolus (n = 73) or IDegLira (n = 72).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3745957401
02HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome
In adults with type 2 diabetes and very high HbA1c, IDegLira (insulin degludec plus liraglutide) led to significantly lower rates of hypoglycemia below 70 mg/dL than basal-bolus insulin.
In plain wordsIn adults with very high HbA1c, a combined insulin and liraglutide product caused fewer low blood sugar events than basal-bolus insulin.
Peptide
Liraglutide
Outcome
DecreaseHypoglycemia <70 mg/dL
Study
n = 145
Comparator
Basal-bolus insulin
Outcome group
Adverse events · Metabolic and weight
Measurements
hypoglycemia rate
26%
IDegLira
hypoglycemia rate
48%
basal-bolus
odds ratio
0.39 ratio
IDegLira vs basal-bolus
Source sentences
Summary
IDegLira resulted in significantly lower rates of hypoglycemia <70 mg/dL (26% vs. 48%, P = 0.008; odds ratio 0.39, 95% CI 0.19, 0.78)
1 context sentence(design, population, supporting numbers)
Summary · context
This randomized trial compared the efficacy and safety of insulin degludec and liraglutide (IDegLira) and basal-bolus among participants with high HbA1c ≥9.0-15.0%, previously treated with 2 or 3 oral agents and/or basal insulin, allocated (1:1) to basal-bolus (n = 73) or IDegLira (n = 72).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3745957402
03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and very high HbA1c, IDegLira (insulin degludec plus liraglutide) led to less weight gain than basal-bolus insulin.
In plain wordsIn adults with very high HbA1c, a combined insulin and liraglutide product caused less weight gain than basal-bolus insulin.
Peptide
Liraglutide
Outcome
DecreaseWeight gain
Study
n = 145
Comparator
Basal-bolus insulin
Outcome group
Body weight · Metabolic and weight
Measurements
weight change
1.24 kg
IDegLira
weight change
5.84 kg
basal-bolus
estimated treatment difference
−4.6 kg
IDegLira vs basal-bolus
Source sentences
Summary
and less weight gain (1.24 ± 8.33 vs. 5.84 ± 6.18 kg, P = 0.001; ETD -4.60, 95% CI -7.33, -1.87).
1 context sentence(design, population, supporting numbers)
Summary · context
This randomized trial compared the efficacy and safety of insulin degludec and liraglutide (IDegLira) and basal-bolus among participants with high HbA1c ≥9.0-15.0%, previously treated with 2 or 3 oral agents and/or basal insulin, allocated (1:1) to basal-bolus (n = 73) or IDegLira (n = 72).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3745957403

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.